SEC Company Response from LUMOS PHARMA, INC. (CIK 0001126234) — Aug 5, 2020
LUMOS PHARMA, INC. (CIK 0001126234)
Date: Aug. 5, 2020 · CIK: 0001126234 · Accession: 0001126234-20-000104
AI Filing Summary & Sentiment
File numbers found in text: 333-240149
Letter
Document
August 5, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549-3720
Attention: Abby Adams
Re:
Lumos Pharma, Inc.
Registration Statement on Form S-3
Filed July 28, 2020
File No. 333-240149
Acceleration Request
Requested Date: August 7, 2020
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Lumos Pharma, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-240149) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Rob Suffoletta at (512) 338-5439 or via email at rsuffoletta@wsgr.com.
[Signature page follows]
Securities and Exchange Commission
August 5, 2020
Page 2
Sincerely,
LUMOS PHARMA, Inc.
Show Raw Text
CORRESP 1 filename1.htm Document August 5, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549-3720 Attention: Abby Adams Re: Lumos Pharma, Inc. Registration Statement on Form S-3 Filed July 28, 2020 File No. 333-240149 Acceleration Request Requested Date: August 7, 2020 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Lumos Pharma, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-240149) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Rob Suffoletta at (512) 338-5439 or via email at rsuffoletta@wsgr.com. [Signature page follows] Securities and Exchange Commission August 5, 2020 Page 2 Sincerely, LUMOS PHARMA, Inc. /s/ Richard J. Hawkins Richard J. Hawkins Chief Executive Officer cc: Bradley J. Powers, General Counsel, Lumos Pharma, Inc. J. Robert Suffoletta, Wilson Sonsini Goodrich & Rosati, P.C.